New and emerging immune‐targeted drugs for the treatment of multiple sclerosis

Multiple sclerosis (MS) is a neurodegenerative disease with a major inflammatory component that constitutes the most common progressive and disabling neurological condition in young adults. Injectable immunomodulatory medicines such as interferon drugs and glatiramer acetate have dominated the MS ma...

Full description

Saved in:
Bibliographic Details
Published in:British journal of clinical pharmacology 2014-07, Vol.78 (1), p.33-43
Main Author: Palmer, Alan M.
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal - therapeutic use
clinical trials
disease‐modifying drugs
drug development
Drugs, Investigational - therapeutic use
Humans
immunomodulatory drugs
Immunosuppressive Agents - therapeutic use
Molecular Targeted Therapy
monoclonal antibodies
Multiple Sclerosis - drug therapy
Multiple Sclerosis - immunology
neuroinflammation
Reviews
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Multiple sclerosis (MS) is a neurodegenerative disease with a major inflammatory component that constitutes the most common progressive and disabling neurological condition in young adults. Injectable immunomodulatory medicines such as interferon drugs and glatiramer acetate have dominated the MS market for over the past two decades but this situation is set to change. This is because of: (i) patent expirations, (ii) the introduction of natalizumab, which targets the interaction between leukocytes and the blood–CNS barrier, (iii) the launch of three oral immunomodulatory drugs (fingolimod, dimethyl fumarate and teriflunomide), with another (laquinimod) under regulatory review and (iv) a number of immunomodulatory monoclonal antibodies (alemtuzumab, daclizumab and ocrelizumab) about to enter the market. Current and emerging medicines are reviewed and their impact on people with MS considered.
ISSN:0306-5251
1365-2125
DOI:10.1111/bcp.12285